{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-25-000123","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.564513+00:00","generated_at":"2026-05-17T14:38:15.177699+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Editas Q2 net loss $53.2M; selects in vivo lead candidate in Sept; BMS CAR T milestone triggered","bullets":["Q2 net loss $53.2M ($0.63/share) vs $67.6M loss a year ago; revenue $3.6M from BMS milestone.","Cash $178.5M at June 30 (down from $269.9M at Dec 2024); runway into Q2 2027.","R&D expense fell $38M to $16.2M on reni-cel discontinuation; restructuring charges $26.1M.","First IND/CTA accepted for CD19 HD Allo CAR T with BMS, triggering milestone payment to Editas.","On track to name lead in vivo candidate Sept 2025, file IND mid-2026, achieve POC by end 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-25-000123","json":"https://secwatch.observer/filing/0001650664-25-000123.json","markdown":"https://secwatch.observer/filing/0001650664-25-000123.md","text":"https://secwatch.observer/filing/0001650664-25-000123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000123/0001650664-25-000123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000123/edit-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:38:15.177699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}